Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
TEL AVIV, Israel, May 01, 2018 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, May 17 at 8:30am Eastern Time to report first quarter ended March 31, 2018 financial results.
Thursday, May 17th @ 8:30am Eastern Time
US Domestic: 877-222-6394
International: 1-703-925-2702
Conference ID: 9993639
Webcast: https://edge.media-server.com/m6/p/zja7xger
Replays, Available through May 31, 2018
US Domestic: 855-859-2056
International: 1-404-537-3406
Conference ID: 9993639
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
